CMB International Securities  Equity Research  Company Update
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
China Consumer Staples
Mkt Cap (RMB mn)
Avg 3 mths to (RMB mn)
52w HighLow (RMB)
Total Issued Shares (mn)
Source Bloomberg
Shareholding Structure
Huhe Haote Investment
Source HKEx
Source Bloomberg
12-mth Price Performance
Source Bloomberg
Cherry-picking amid a de-risking
mentality our top picks CRB
Mengniu Feihe  21 Jan 2022
Marketing feedback  inflation 
price hikes are key words appeared
in every meeting  23 Nov 2021
Structural merits look prominent
amid transitional headwind and any
stagflation expectation  2 Nov
SHSZ300 (rebased)
BUY (Maintain)
(Previous TP                     RMB500)
UpDownside
We trim our 2021E net profits by 15% to RMB8902mn subsequent to our
incorporation of a 09pp higher opex ratio (of 287%) for 4Q21 due to any
promotional expense for the Winter Olympics In other words we lowered our
4Q21E net profit estimate to RMB958mn which is now about 2% below
consensus Meanwhile we leave our 2021E top line largely unchanged as we
expect 4Q shipment growth (116% YoY) to sequentially improve from 86% in
3Q We extrapolated our revised forecasts and as such we cut 4% of our 2022E
net profits which explained our lowered TP of RMB465 (from RMB500) We are
buy-rated but we prefer CR Beer (291HK Buy) and Mengniu (2319HK Buy)
within our China Consumer Staples coverage universe for a potentially lower
earnings volatility into the result seasons
 A steady 4Q top line Sales in liquid milk improved vs 3Q21 when IMF
continued to track strongly Based on Nielsen data Yilis market share in IMF
expanded 16ppt YoY to 71% in Nov 2021 despite regional outbreaks in the
country during the quarter Low temp milk recorded steady top line growth in
by the sector at the current stage given still limited scale high cold chain
logistic cost and the need of time to grow consumer habits
 4Q21 margins still under presssure 4Q21 margins went under relatively
selling expense ratio largely due to increased advertising campaigns
including those for Winter Olympics It is unlikely in our view to see significant
keep investing in emerging categories such as IMF low temp milk cheese
Management expected full-year NPM to improve by about 05ppt YoY
 Valuation Our TP is based on an updated 285x (from 290x) end-22E PE
which still represents 1sd above its 3-year average In our view our
methodology reflects Yilis solid growth roadmap which likely manifests into a
guided approximately 05ppt margins expansion per annum
(YE 31 Dec)
Revenue (RMB mn)
YoY growth (%)
YoY growth (%)
Consensus EPS (RMB)
Net gearing (%)
Source Company data Bloomberg CMBIS estimates
Yili Industrial (600887 CH)
Promotional expense on Winter Olympics could
weigh on 4Q results
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 1 Revenue growth Mengniu vs Yili
Source Company data CMBIS estimates
Figure 2 EBIT margins Mengniu vs Yili
Source Company data CMBIS estimates
Figure 3 Revenue breakdown 2017-23E
Source Company data CMBIS estimates
Figure 4 Gross profits breakdown by product
Source Company data CMBIS
Figure 5 1-year forward PE chart
Source Bloomberg CMBIS estimates
Figure 6 Trailing PB chart
Source Bloomberg CMBIS estimates
1-yr fwd PE
1-yr trailing PB
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
FY19A FY20A FY21E FY22E FY23E  YE 31 Dec (RMB mn)
FY19A FY20A FY21E FY22E FY23E
16462 20762 25631 30119 35479  Change in working capital
33254 34534 39414 45233 51020  Net cash fr operating act
(1958) (2442) (2821) (3252) (3688)  Capex  investments
(21070) (21538) (23603) (26445) (29298)  Acquisition
Administration expenses
(4780) (5363) (6095) (6926) (7465)  Others
3688  Net cash fr investing act
9919 12537 15114 17944  Change of Debts
Finance costs net
(456)  Others
Investment gainsloss
1516  Net cash fr financing act
Non-operating
Pre-tax profit
8150 10497 12552 15016  Net change in cash
Cash at the beginning of the
(1243) (1051) (1575) (1883) (2252)  Exchange difference
Less Minority interests
(21)  Cash at the end of the year 11325 11695
8902 10648 12743  Less pledged cash
YE 31 Dec (RMB mn)
FY19A FY20A FY21E FY22E FY23E  YE 31 Dec
FY19A FY20A FY21E FY22E FY23E
Non-current assets
PPEFixed assets
2530  Others
Other non-current assets
8685  PL ratios (%)
9879  Pre-tax margin
3087  Net margin
9307 10519 11710  Effective tax rate
Balance sheet analysis
6357  Net receivable days
13618 17975 19390 21914 24395  Inventory turnover days
9836 11488 12790 14353  Net payable days
Net debt to equity (%)
Non-current liabilities
4537  Returns (%)
Other non-current liabilities
211  EPS (RMB)
Shareholders equity
Source Company data CMBIS estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Yili Industrial (600887 CH) NDR key takeaways
2022-to-date performance and some topics of major market interest
 A steady 4Q top line Sales in liquid milk improved vs 3Q21 IMF continued to track
strongly Based on Nielsen data Yilis market share in IMF expanded 16pp YoY to
71% in Nov 2021 despite regional outbreaks in the country during the quarter Low
temp milk recorded steady top line growth in the quarter but has not yet broken even
scale high cold chain logistic cost and the need of time to grow consumer habits
 4Q21 margins still under presssure 4Q21 margins went under relatively high
expense ratio largely due to increased advertising campaigns including those for Winter
Olympics It is unlikely in our view to see significant reduction in selling expense ratio
as IMF low temp milk cheese Management expected full year NPM expected to
improve by about 05pp YoY
 2022E outlook and longer-term targets Management guided for a healthy pace of
revenue growth in 2022E and to rank among the top 3 players globally by 2025E with
steady growth in liquid milk ï¼Œa 25% CAGR in IMF and high growth in smaller
margin expansion so as to achieve 9-10% NPM by 2025E Management also expects
the sector to see further consolidation going forward
 Cost pressure from raw milk price hike expect to ease in 2022E Raw milk price
increase decelerated in 4Q21 QoQ with the increase falling to LSD in Oct and Nov
2021 Management estimated raw milk price to record a HSD increase YoY for 2021
and expect the price to relatively stabilize at high levels in 2022E which should lead to
2022E after it has increased the prices of some SKUs in Jan and end 2021
 Development of IMF business and the strategic investment in Ausnutria The IMF
25% by 2025E before the strategic investment in Ausnutria According to management
it could even beat the target with synergies from Ausnutria in terms of supply chain
integration product extension (to other health care products) and channels expansion
Financial impact from the merger would be reflected in 2Q22 according to management
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Disclosures  Disclaimers
Analyst Certification
The research analyst who is primary responsible for the content of this research report in whole or in part certifies that with respect to the securities
or issuer that the analyst covered in this report (1) all of the views expressed accurately reflect his or her personal views about the subject securities
in this report
Besides the analyst confirms that neither the analyst nor hisher associates (as defined in the code of conduct issued by The Hong Kong Securities
and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue
of this report (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report (3) serve
covered in this report
 Stock with potential return of over 15% over next 12 months
 Stock with potential return of 15% to -10% over next 12 months
 Stock with potential loss of over 10% over next 12 months
 Stock is not rated by CMBIS
OUTPERFORM                     Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM             Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM                 Industry expected to underperform the relevant broad market benchmark over next 12 months
CMB International Securities Limited
Address 45F Champion Tower 3 Garden Road Hong Kong Tel (852) 3900 0888   Fax (852) 3900 0800
CMB International Securities Limited (CMBIS) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary
of China Merchants Bank)
Important Disclosures
There are risks involved in transacting in any securities  The information contained in this report may not be suitable for the purposes of all investors  CMBIS does not
provide individually tailored investment advice This report has been prepared without regard to the individual investment objectives financial position or special
requirements  Past performance has no indication of future performance and actual events may differ materially from that which is contained in the report  The value
of and returns from any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets
consult with a professional financial advisor in order to make their own investment decisions
This report or any information contained herein have been prepared by the CMBIS solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s)
to whom it is distributed  This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any
transaction  Neither CMBIS nor any of its affiliates shareholders agents consultants directors officers or employees shall be liable for any loss damage or expense
whatsoever whether direct or consequential incurred in relying on the information contained in this report  Anyone making use of the information contained in this report
does so entirely at their own risk
The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable CMBIS
and forecasts on an AS IS basis  The information and contents are subject to change without notice CMBIS may issue other publications having information and or
report As a result recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any
responsibility in respect thereof This report is for the use of intended recipients only and this publication may not be reproduced reprinted sold redistributed or published
in whole or in part for any purpose without prior written consent of CMBIS
For recipients of this document in the United Kingdom
This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended
from time to time)(The Order) or (II) are persons falling within Article 49(2) (a) to (d) (High Net Worth Companies Unincorporated Associations etc) of the Order and
may not be provided to any other person without the prior written consent of CMBIS
For recipients of this document in the United States
CMBIS is not a registered broker-dealer in the United States  As a result CMBIS is not subject to US rules regarding the preparation of research reports and the
independence of research analysts  The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research
analyst with the Financial Industry Regulatory Authority (FINRA)  The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the
analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report This report is intended for distribution in the United States
solely to major US institutional investors as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 as amended and may not be furnished to any other
person in the United States Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not
distribute or provide this report to any other person Any US recipient of this report wishing to effect any transaction to buy or sell securities based on the information
provided in this report should do so only through a US-registered broker-dealer
For recipients of this document in Singapore
This report is distributed in Singapore by CMBI (Singapore) Pte Limited (CMBISG) (Company Regn No 201731928D) an Exempt Financial Adviser as defined in the
Financial Advisers Act (Cap 110) of Singapore and regulated by the Monetary Authority of Singapore CMBISG may distribute reports produced by its respective foreign
entities affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations Where the report is distributed
in Singapore to a person who is not an Accredited Investor Expert Investor or an Institutional Investor as defined in the Securities and Futures Act (Cap 289) of
Singapore CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law Singapore recipients should contact
CMBISG at 65 6350 4400 for matters arising from or in connection with the report